RESUMO
No disponible
No disponible
Assuntos
Humanos , Masculino , Adulto , Pilomatrixoma/diagnóstico , Dermatoses do Couro Cabeludo/diagnóstico , Diagnóstico DiferencialRESUMO
La morfea panesclerótica de la infancia es una rara variante de esclerodermia localizada, que aparece típicamente en la edad pediátrica, y que se caracterizapor la rápida progresión de una fibrosis cutánea profunda que alcanza fascia y músculo, determinando la aparición de contracturas articularesen flexión y ulceración cutánea.Aunque las manifestaciones de la esclerodermia sistémica están generalmente ausentes, este proceso afecta de forma importante la calidad de vida,por lo que el pronóstico es malo. En algunos casos los agentes inmunosupresores pueden retrasar el curso de la enfermedad. Recientemente se hancomunicado casos de mejoría de este cuadro mediante la utilización de la fototerapia. Aportamos un nuevo caso de esta entidad (AU)
Panesclerotic morphea of the childhood is a rare variant of localiced scleroderma that appears typically in the pediatric age, it is characterized by thefast progression of deep cutaneous fibrosis that reaches fascia and muscle, determining the appearance of articular contractures in flexion and cutaneousulceration. Although the features of systemic scleroderma are generally absent, this process affects severely the quality of life, the reason whythe prognosis is bad. In some cases the inmunosupressive agents can delay the course of the disease. Recently cases of improvement of this disorderwith phototerapia have been communicated. We described a new case of this entity (AU)
Assuntos
Humanos , Feminino , Criança , Esclerodermia Localizada/tratamento farmacológico , Esclerodermia Localizada/diagnóstico , Índice de Gravidade de Doença , Prostaglandinas/uso terapêutico , Terapia PUVARESUMO
Severe combined immunodeficiency (SCID) is a heterogeneous group of disorders characterized by a defect of T and B cell immunity with a genetic origin in most cases. Although the X-linked recessive form is most common (60-70%), there are autosomal recessive forms (20%) and spontaneous mutations. While SCID may present with many nosocomial infections, dermatophyte infections are not common. We reported a case of SCID which was associated with a widespread skin infection with Trichophyton mentagrophytes.
Assuntos
Imunodeficiência Combinada Severa/complicações , Tinha do Couro Cabeludo/complicações , Antifúngicos/uso terapêutico , Feminino , Griseofulvina/uso terapêutico , Humanos , Lactente , Tinha do Couro Cabeludo/tratamento farmacológicoRESUMO
Alopecia areata is nonscarring telogenic alopecia of autoimmune etiology. It is estimated to be the presenting complaint in 2 % of dermatologic consultations, and can appear at any age although it is more common in young patients. Treatment depends on several factors, such as extent of the disease and age, and may be local or systemic. Local treatments aim to achieve hair regrowth, but do not alter the underlying condition, whereas systemic treatments can modify the course of the disease. In neither case does treatment provide a cure. In this article, we review most of the therapeutic options described in the literature for alopecia areata.
Assuntos
Alopecia em Áreas/tratamento farmacológico , Corticosteroides/uso terapêutico , Algoritmos , Humanos , ImunoterapiaRESUMO
La alopecia areata es una alopecia no cicatricial telogénica de base autoinmune. Se estima que origina un 2 % de las consultas dermatológicas y puede aparecer a cualquier edad, aunque es más frecuente en pacientes jóvenes. Su tratamiento va a depender de varios factores, fundamentalmente de la extensión de la enfermedad, de la edad del paciente, así como de medidas locales y sistémicas. Mientras que los tratamientos locales tienen como objetivo conseguir el recrecimiento piloso, sin influir en la evolución de la enfermedad, los tratamientos sistémicos pueden interferir en la evolución de la misma, siendo ambos medidas paliativas. En este trabajo revisamos la mayoría de las opciones terapéuticas descritas en la literatura para la alopecia areata (AU)
Alopecia areata is nonscarring telogenic alopecia of autoimmune etiology. It is estimated to be the presenting complaint in 2 % of dermatologic consultations, and can appear at any age although it is more common in young patients. Treatment depends on several factors, such as extent of the disease and age, and may be local or systemic. Local treatments aim to achieve hair regrowth, but do not alter the underlying condition, whereas systemic treatments can modify the course of the disease. In neither case does treatment provide a cure. In this article, we review most of the therapeutic options described in the literature for alopecia areata (AU)
Assuntos
Humanos , Masculino , Feminino , Alopecia em Áreas/diagnóstico , Alopecia em Áreas/terapia , Corticosteroides/uso terapêutico , Ciclosporina/uso terapêutico , Triancinolona Acetonida/uso terapêutico , Imunoterapia/métodos , Fototerapia/métodos , Fotoquimioterapia , Sulfassalazina/uso terapêutico , Antralina/uso terapêutico , Minoxidil/uso terapêutico , Administração Tópica , Terapia PUVA , Prostaglandinas/uso terapêutico , Tacrolimo/uso terapêutico , Valerato de Betametasona/uso terapêutico , Irritantes/uso terapêutico , Metilprednisolona/uso terapêutico , Fatores Imunológicos/uso terapêuticoRESUMO
No disponible
No disponible
Assuntos
Feminino , Pessoa de Meia-Idade , Humanos , Erupções Acneiformes/complicações , Erupções Acneiformes/diagnóstico , Erupções Acneiformes/tratamento farmacológico , Metronidazol/uso terapêutico , Imuno-Histoquímica/métodos , Diagnóstico Diferencial , Queratinócitos , Queratinócitos/patologia , Queratinócitos/fisiologia , Multimerização Proteica , Multimerização Proteica/fisiologiaAssuntos
Erupções Acneiformes/induzido quimicamente , Erupções Acneiformes/tratamento farmacológico , Anticorpos Monoclonais/efeitos adversos , Toxidermias/tratamento farmacológico , Toxidermias/etiologia , Metronidazol/uso terapêutico , Doença Aguda , Anticorpos Monoclonais Humanizados , Cetuximab , Feminino , Humanos , Pessoa de Meia-Idade , Indução de RemissãoRESUMO
La capecitabina es un agente antineoplásico utilizado para el tratamiento de pacientes con metástasis de tumores sólidos (mama y colon) en estadio avanzado. Se reconocen distintos efectos adversos, entre los cuales se encuentran los cutáneo-mucosos y, en concreto, la hiperpigmentación. Presentamos un caso de hiperpigmentación cutánea localizada secundaria a capecitabina en una mujer intervenida de cáncer de mama y en tratamiento durante un mes con este fármaco. El inicio del tratamiento se asoció con disestesias a nivel de manos y pies, así como aumento de la pigmentación de las mismas. La etiopatogénesis de tales manifestaciones es desconocida. Otros efectos adversos descritos, desde el punto de vista dermatológico, asociados a este fármaco asientan en uñas produciendo onicolisis, fragilidad, decoloración y distrofia
Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesias and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy
Assuntos
Feminino , Pessoa de Meia-Idade , Humanos , Hiperpigmentação/induzido quimicamente , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológicoRESUMO
Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesias and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy.
